The application of IL-6 on breast cancer cells inhibits proliferation in estrogen receptor-positive cells, while high circulating IL-6 levels are correlated with a poor prognosis in breast cancer patients, indicating discrepancies and the distinct roles of this cytokine [33]. Here, ESR1 is linked to breast carcinoma.